Company Profile

TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.

Employees

Sector

Biotechnology & Medical Research

More about the company

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	+67.53%

01/18/01	TxCell : Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares	PR
23/18/23	TxCell : Sangamo Therapeutics to Acquire TxCell	PR
09/18/09	TxCell : exercises in-license option to the University of British Columbia’s intellectual property rights of the HLA-A2 CAR-Treg program	PU
21/18/21	TxCell : First in vivo proof-of-concept data with CD8+ CAR-Treg presented at FOCIS 2018	PU
28/18/28	TxCell : to present its latest manufacturing process achievements at the 3rd Annual Bioprocessing of Advanced Cellular Therapies Congress	PU

03/18/03	TxCell : acquisition par Sangamo finalisée
27/18/27	TxCell : retrait obligatoire ce jeudi
26/18/26	TxCell : près de sept millions d'actions apportées à l'OPAS
23/18/23	TXCell : Sangamo Therapeutics dépasse les 90%
15/18/15	TxCell : 'la rencontre avec Sangamo était une évidence'

Manager	Title	Age	Since
Sandrine Boulet COO	Chief Operating Officer	50	-
Pierre Desreumaux PRN	Corporate Officer/Principal	-	-
Bernard Malissen PRN	Corporate Officer/Principal	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TXCELL	-.--%	-.--%	-	-	0
WUXI APPTEC CO., LTD.	-2.48%	-2.22%	+55.85%	+79.12%	5.35TCr
ARGENX SE	-0.55%	-6.57%	+58.09%	+128.31%	5.42TCr
INSMED INCORPORATED	-5.60%	-2.15%	+11.16%	+420.46%	2.37TCr
BIONTECH SE	-1.55%	-4.11%	-20.21%	-17.75%	2.28TCr
WUXI BIOLOGICS (CAYMAN) INC.	+2.84%	+4.35%	+43.48%	-6.16%	1.95TCr
GENMAB A/S	+1.87%	+4.16%	+38.13%	-26.42%	1.78TCr
PHARMAESSENTIA CORPORATION	-2.72%	-4.04%	+187.08%	+362.09%	1.6TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.95%	-3.04%	+45.39%	+655.15%	1.54TCr
EXELIXIS, INC.	-0.81%	+0.92%	+24.92%	+189.61%	1.41TCr
Average	-1.01%	-1.68%	+49.32%	+198.27%	2.63TCr
Weighted average by Cap.	-1.32%	-1.99%	+48.59%	+163.21%

TxCell Share Price

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Press Releases: TxCell

News in other languages: TxCell

Managers and Directors: TxCell

Bio Therapeutic Drugs

Company Profile